Patents by Inventor Ewald M. Aydt

Ewald M. Aydt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE
    Publication number: 20110257114
    Abstract: The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-?-D-mannopyranosyloxy)-phenyl]hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 20, 2011
    Applicant: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. AYDT, Remo Kranich, Karin Vollhardt, Gerhard Wolff
  • Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-?-D-mannopyranosyloxy)-phenyl] hexane
    Patent number: 8039601
    Abstract: The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-?-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: October 18, 2011
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich, Karin Vollhardt, Gerhard Wolff
  • NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS
    Publication number: 20110152291
    Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: March 1, 2011
    Publication date: June 23, 2011
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. AYDT, Remo Kranich, Anke S. Busemann
  • NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY
    Publication number: 20110142765
    Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or selectin binding.
    Type: Application
    Filed: February 23, 2011
    Publication date: June 16, 2011
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. AYDT, Remo Kranich
  • Aromatic compounds and their use in medical applications
    Patent number: 7923473
    Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: April 12, 2011
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich, Anke S. Busemann
  • Hydroxylated aromatic compounds
    Patent number: 7919532
    Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: April 5, 2011
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich
  • NOVEL AROMATIC NITRO COMPOUNDS
    Publication number: 20110053939
    Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning—X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 3, 2011
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. AYDT, Remo Kranich
  • Aromatic nitrocatechol compounds and their use for modulating processes mediated by cell adhesion molecules
    Patent number: 7851501
    Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: December 14, 2010
    Assignee: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich
  • Pharmaceutical Composition for the Treatment of IL-8 mediated diseases
    Publication number: 20100298245
    Abstract: A compound of formula (I) can be used for the preparation of a pharmaceutical composition for the treatment, diagnosis or prophylaxis of Interleukin-8 related to viral infections.
    Type: Application
    Filed: February 14, 2008
    Publication date: November 25, 2010
    Applicant: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Daniel Bock, Gerhard Wolff, Michael Meyer
  • Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions
    Publication number: 20100190851
    Abstract: A compound of formula (I), a salt of this compound or an isomeric or polymorphic form thereof can be used for the preparation of a cosmetic or dermatological composition, which is useful for the treatment or prophylaxis of itching or skin ageing caused by a combination of intrinsic and extrinsic factors.
    Type: Application
    Filed: January 16, 2008
    Publication date: July 29, 2010
    Inventors: Remo Kranich, Ewald M. Aydt, Daniel Bock, Gerhard Wolff
  • Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane
    Publication number: 20100144654
    Abstract: The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-?-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.
    Type: Application
    Filed: September 7, 2007
    Publication date: June 10, 2010
    Applicant: Revotar Biophamaceuticals AG
    Inventors: Ewald M. Aydt, Remo Kranich, Karin Vollhardt, Gerhard Wolff
  • Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
    Publication number: 20100093653
    Abstract: A compound of formula (I) or a polymorphic form thereof can be used for the preparation of a cosmetic or dermato logical composition for the treatment of skin ageing.
    Type: Application
    Filed: September 7, 2007
    Publication date: April 15, 2010
    Applicant: Revotar Biopharmaceuticals AG
    Inventors: Ewald M. Aydt, Daniel Bock, Karin Vollhardt, Gerhard Wolff
  • Novel Aromatic Nitro Compounds
    Publication number: 20090105280
    Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: September 20, 2006
    Publication date: April 23, 2009
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. Aydt, Remo Kranich
  • NOVEL MULTI-CYCLIC COMPOUNDS
    Publication number: 20090030015
    Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) or (IIa) or (IIb) and a pharmaceutically acceptable carrier wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: September 20, 2006
    Publication date: January 29, 2009
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Remo Kranich, Ewald M. Aydt, Anke S. Busemann
  • Novel Hydroxylated Aromatic Compounds
    Publication number: 20080207741
    Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: September 20, 2006
    Publication date: August 28, 2008
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. Aydt, Remo Kranich
  • Novel Aromatic Compounds and Their Use in Medical Applications
    Publication number: 20080207639
    Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
    Type: Application
    Filed: September 20, 2006
    Publication date: August 28, 2008
    Applicant: REVOTAR BIOPHARMACEUTICALS AG
    Inventors: Ewald M. Aydt, Remo Kranich, Anke S. Busemann